Market news
The proposed transaction would create a Nasdaq-listed company focused on NET-targeting therapies, combining four clinical programs while transferring majority ownership to Santersus shareholders. Key Investor TakeawaysXenetic Biosciences (NASDAQ:XBIO) has signed a definitive share exchange agreement to acquire privately held Santersus AG in an all-stock transaction.
The combined company is expected to continue to trade on the Nasdaq Capital Market as Santersus Bio, Inc."The Proposed Transaction is expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on a single high-impact therapeutic target: neutrophil extracellular traps, or NETs.
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
This is the newest page. Registered accounts read further back.